About

Robert V. Condon III is a partner in the Corporate department of our New York office and a member of our Capital Markets and Finance practice groups.

Robert enjoys a comprehensive broad-based corporate practice that involves counseling clients on public and private securities offerings, securities law compliance, mergers and acquisitions, corporate finance, structured finance, private equity and corporate governance.

He regularly advises investment banks and issuers on private placements, IPOs, and follow-on offerings for emerging and established companies, primarily in technology and healthcare markets. His corporate finance practice includes both bank and borrower representation, from single-lender to large syndicated financings, secured and unsecured, and workouts and restructurings.

Notable capital markets highlights include advising on a $30 million U.S. public offering of a foreign emerging pharmaceutical company; a $35 million U.S. initial public offering of a foreign orphan drug pharmaceutical company; and a $47 million U.S. public offering of American depositary shares of a foreign medical device manufacturer. He has also represented the administrative agent and lead arranger of $500 million secured credit facility.

His diverse practice includes providing counsel to public and private pension, family office and fund-of-funds investors in connection with private equity investments and secondary market purchases and sales of partnership interests. He also represents lessees, lessors, and investors in lease, equipment and project financings, with particular experience in cross-border utility lease transactions, and in domestic aircraft, railcar and solar leasing. Furthermore, he provides corporate support to the Real Estate practice group in relation to entity formations, special purpose entity requirements, and syndications.

Representative Client Work

  • $30 million U.S. public offering of a foreign emerging pharmaceutical company
  • $35 million U.S. initial public offering of a foreign orphan drug pharmaceutical company
  • $47 million U.S. public offering of American depositary shares of a foreign medical device manufacturer
  • Represented the administrative agent and lead arranger of $500 million secured credit facility
  • Represented public and private pension, family office and fund-of-funds investors in connection with private equity investments and secondary market purchases and sales of partnership interests
  • Represented lessees, lessors and investors in lease, equipment and project financings, with particular experience in cross-border utility lease transactions, and in domestic aircraft, railcar and solar leasing
  • Provide corporate support to real estate practice group in entity formation, special purpose entity requirements and syndications

Recent Activity